Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of methylprednisolone pulses in neuroendocrine cell hyperplasia of infancy (CORTICONEHI)
2023-508132-65-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of methylprednisolone in Neuroendocrine Cell Hyperplasia, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Oxygen therapy requirement at 18 months. Planned start Jun 2025; status: authorised.
02
Drugs
methylprednisolone
03
Conditions
Neuroendocrine Cell Hyperplasia
Beyond the preview
Go deeper on 2023-508132-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508132-65-00.